New and Modified Applications

The disease indication of new drug development is usually considered for maximally efficient approval of the drugs, while additional indications considered under the meaningful data supports of clinical trials or post-approval studies. It is especially true when a disease indication faces significant challenges in the implementations of the clinical trials, in such cases like, the chronic disease, secondary disease, excluded sub-populations of the patients, organ disfunctioning syndrome, lethal or sporadic diseases, etc. Studies in NHP can be an efficient way to provide the convinced feasibility and demonstration of the new applications in the closest clinical setting. 


 •  Spontaneous diseases in monkeys, such as obesity, fatty liver, diabetes, infertility, osteoarthritis, chronic diarrhea,

    coagulopathy, dysmenorrhea, depression, benign prostate hyperplasia, age-related diseases, etc.

 •  Sporadic and urgent diseases: acute organ failure, shock, stroke, and wound….

 •  Accompanying the primary disease, the indications of secondary disease can facilitate the study of targeted therapy as

    well as the beneficial effects in secondary disease treatment

 •  Differentiation and precision applications: allergy, organ transplantation, local immunity, and breast cancer….

 •  Medication applications in special populations: pregnancy, infantile, juvenile, and developmental, physiological, ….

 •  Medication applications in disease sub-populations: immune-deficiency, chronic diseases, organ function insufficient,

    and pre-disease stages….

 •  Medical devices: surgery procedures, organ local interventions, imaging analysis and examinations